B4GALNT1 and Parkinson disease: As a result of systemic administration of GM1-OS to heterozygous B4galnt1-deficient mice (B4galnt-1+/-), it was determined that PD-induced physical symptoms were relieved, and decreased αSyn level in the SN and tyrosine hydroxylase level increased in these mice [40].